Edaravone Market Set to Reach USD 1.85 Billion by 2031 | Injection Segment Dominates 82% of Global Demand

Market Size & Growth:

The global Edaravone market was valued at USD 1.05 billion in 2024 and is projected to reach USD 1.85 billion by 2031, growing at a CAGR of 7.1% during the forecast period. Growth is driven by the increasing ALS patient population, rising incidences of stroke, and improved healthcare infrastructure supporting access to specialized medications.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/edaravone-market?Juli

Edaravone is a pharmaceutical agent that acts as a free-radical scavenger to reduce oxidative stress, primarily used in the treatment of amyotrophic lateral sclerosis (ALS) and acute ischemic stroke.

Recent Developments:

United States
✅ October 2025: U.S. hospitals began integrating edaravone infusion protocols in stroke rehabilitation centers, increasing adoption in post-stroke care.

✅ August 2025: Sun Pharmaceutical launched a reformulated intravenous edaravone with improved bioavailability for hospital use.

✅ May 2025: BiVACOR Inc. partnered with U.S. clinics to study edaravone's synergistic effects with neuroprotective devices for ALS management.

Global
✅ September 2025: Mitsubishi Tanabe Pharma expanded edaravone distribution to European and Asia-Pacific markets with patient-assistance programs to improve therapy accessibility.

✅ June 2025: Unichem Laboratories Ltd introduced generic edaravone injection formulations in India and Southeast Asia, reducing cost barriers.

✅ March 2025: Clinical trials in Japan demonstrated improved long-term outcomes in ALS patients using combination therapy of edaravone and advanced rehabilitation techniques.

Competitive Landscape:
Sun Pharmaceutical Industries Ltd, Unichem Laboratories Ltd, UCB India Ltd, Piramal Healthcare, Mitsubishi Tanabe Pharma, Simcere, Taj Pharmaceuticals Ltd, ABIOMED, Berlin Heart, and BiVACOR Inc. Together, these players account for approximately 70-75% of the global market, leveraging product innovations, regional expansions, and strategic partnerships to enhance market penetration.

Market Segmentation:

By Product Type:
Injection: 82% market share (USD 861 million, 2024): Widely preferred due to controlled delivery, immediate bioavailability, and hospital-based administration. Oral: 18% market share (USD 189 million, 2024): Gaining popularity in outpatient care due to patient convenience and home-based therapy options.

By Distribution Channel:
Hospital Pharmacies: 65% (USD 682 million, 2024): Major contributor due to prescription requirements and supervised administration. Retail Pharmacies: 25% (USD 263 million, 2024): Facilitates accessibility for ongoing ALS management and post-stroke therapy. Online Pharmacies: 10% (USD 105 million, 2024): Rapidly growing due to e-pharmacy adoption and home delivery convenience.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=edaravone-market?juli

Mergers & Acquisitions:

United States
✅ July 2025: ABIOMED acquired a neuropharmaceutical distribution startup to streamline edaravone delivery and patient access.

✅ February 2025: Mitsubishi Tanabe Pharma partnered with a Japanese biotechnology firm to co-develop new edaravone analogs with improved pharmacokinetics.

✅ January 2025: Berlin Heart formed a strategic alliance with European clinics to expand edaravone therapy adoption for ALS patients.

Get Customized Report as per your Business Requirements: https://www.datamintelligence.com/customize/edaravone-market?Juli

Regional Insights:

North America 38% market share (USD 399 million, 2024):
The U.S. dominates the region due to high awareness of ALS therapies, advanced hospital infrastructure, and favorable reimbursement policies. The early adoption of IV edaravone for stroke management is further driving market penetration, supported by well-established neurology centers and robust healthcare insurance coverage.

Europe 28% (USD 294 million, 2024):
Market growth is supported by regulatory approvals, extensive hospital pharmacy networks, and patient assistance programs across key countries such as Germany, France, and the UK. Increasing physician awareness of edaravone's efficacy in ALS and ischemic stroke treatment is enhancing adoption in both hospital and retail pharmacy settings.

Asia-Pacific 24% (USD 252 million, 2024; CAGR 8.3%):
The region exhibits the fastest growth due to rising ALS prevalence, improved availability of generic edaravone, and expanding healthcare infrastructure in China, Japan, and India. Growing government healthcare initiatives and urban hospital expansions are further driving market uptake, while increased awareness and affordability are facilitating wider patient access.

Latin America, Middle East & Africa 10% (USD 105 million, 2024):
Growth in these regions is supported by government healthcare programs, rising awareness of neurological disorders, and increasing adoption of edaravone in urban hospitals. Market expansion remains limited by infrastructure gaps and high treatment costs in rural areas, but urban centers are emerging as primary revenue contributors.

Conclusion
The Edaravone Market is poised for steady growth, fueled by innovations in drug delivery, rising disease prevalence, and expanding global access. Companies focusing on novel formulations, geographic expansion, and strategic partnerships are likely to dominate the market. Over the next decade, the market presents significant opportunities in oral therapy adoption, emerging market penetration, and integration with neurorehabilitation technologies, offering transformative value to both healthcare providers and patients.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots

✅ Market Volatility & Emerging Risks Analysis

✅ Quarterly Industry Report Updated

✅ Live Market & Pricing Trends

✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.